Core Insights - The AI-enabled Shenzhen Pharmaceutical and Medical Device Industry High-Quality Development Conference successfully took place, focusing on how data and algorithms can enhance drug development, precision medicine, and health management [1] - Shenzhen is a major hub for AI pharmaceutical companies, with 18 AI drug companies representing 17% of the national total, including notable firms like Crystal Technology, Star Pharmaceutical, and Eglen Pharmaceuticals [1] - Shenzhen's AI drug clinical pipelines are advancing rapidly, with 10 AI pipelines entering clinical stages, accounting for 10% globally and 30% nationally [1] - The "AI + Medical Devices" industry in Shenzhen is also leading nationally, with products concentrated in various disease areas such as cardiovascular, neurological, and oncology [1] Product and Data Development - The conference announced a list of outstanding AI + pharmaceutical and medical device products, including high-throughput peptide synthesizers and AI diagnostic models for chronic diseases [2] - The biomedicine and high-end medical device sectors are key strategic emerging industry clusters in Shenzhen, relying on a high-quality data flow environment for digital and intelligent development [2] - Shenzhen Data Exchange introduced five high-quality medical data products focused on public health, chronic disease management, and vaccination, providing a solid data foundation for AI pharmaceutical companies [2] - The Shenzhen Data Exchange has made breakthroughs in data property registration, trusted circulation, and revenue distribution, creating replicable and scalable innovative results in various fields, including healthcare [2]